Cantor Fitzgerald L. P. Increases Position in Zevra Therapeutics, Inc. $ZVRA

Cantor Fitzgerald L. P. raised its position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 487.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 117,576 shares of the company’s stock after buying an additional 97,575 shares during the period. Cantor Fitzgerald L. P. owned about 0.21% of Zevra Therapeutics worth $1,118,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Zevra Therapeutics by 6.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock valued at $238,000 after buying an additional 1,812 shares during the period. Strs Ohio purchased a new position in Zevra Therapeutics during the 1st quarter valued at about $125,000. Geode Capital Management LLC grew its position in Zevra Therapeutics by 0.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,242,386 shares of the company’s stock valued at $10,948,000 after acquiring an additional 9,275 shares in the last quarter. Creative Planning acquired a new position in Zevra Therapeutics in the 2nd quarter valued at about $92,000. Finally, Legal & General Group Plc increased its stake in Zevra Therapeutics by 26.8% during the second quarter. Legal & General Group Plc now owns 935,677 shares of the company’s stock worth $8,243,000 after purchasing an additional 197,940 shares during the period. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Stock Down 3.5%

Shares of NASDAQ:ZVRA opened at $9.55 on Thursday. Zevra Therapeutics, Inc. has a fifty-two week low of $6.19 and a fifty-two week high of $13.16. The firm’s 50 day moving average price is $9.02 and its 200 day moving average price is $9.10. The company has a quick ratio of 5.63, a current ratio of 5.68 and a debt-to-equity ratio of 0.40. The stock has a market cap of $560.68 million, a price-to-earnings ratio of 7.18 and a beta of 0.91.

Insider Activity

In other news, insider Joshua Schafer sold 10,500 shares of Zevra Therapeutics stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $9.19, for a total transaction of $96,495.00. Following the completion of the sale, the insider directly owned 62,278 shares of the company’s stock, valued at approximately $572,334.82. The trade was a 14.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Neil F. Mcfarlane sold 91,000 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $9.38, for a total transaction of $853,580.00. Following the transaction, the chief executive officer owned 364,350 shares of the company’s stock, valued at approximately $3,417,603. The trade was a 19.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 114,158 shares of company stock valued at $1,062,878 over the last quarter. Company insiders own 2.40% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on ZVRA shares. Weiss Ratings raised shares of Zevra Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a research report on Tuesday, March 10th. BTIG Research started coverage on shares of Zevra Therapeutics in a report on Monday. They issued a “buy” rating and a $23.00 price objective for the company. Wall Street Zen downgraded shares of Zevra Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. HC Wainwright set a $26.00 target price on shares of Zevra Therapeutics in a report on Tuesday, December 30th. Finally, Guggenheim set a $23.00 price target on shares of Zevra Therapeutics and gave the company a “buy” rating in a research report on Tuesday, March 10th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $23.00.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.